Oragenics, Inc. (OGEN)
0.5399
+0.02
(+3.81%)
USD |
NYAM |
Aug 26, 13:06
Oragenics Enterprise Value : -1.518M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | -1.518M |
| August 24, 2026 | -1.520M |
| August 21, 2026 | -1.495M |
| August 20, 2026 | -1.428M |
| August 19, 2026 | -1.472M |
| August 18, 2026 | -1.401M |
| August 17, 2026 | -1.450M |
| August 14, 2026 | -1.460M |
| August 13, 2026 | -1.472M |
| August 12, 2026 | -1.444M |
| August 11, 2026 | -1.388M |
| August 10, 2026 | -1.392M |
| August 07, 2026 | -1.383M |
| August 06, 2026 | -1.412M |
| August 05, 2026 | -1.428M |
| August 04, 2026 | -1.383M |
| August 03, 2026 | -1.476M |
| July 31, 2026 | -1.608M |
| July 30, 2026 | -1.652M |
| July 29, 2026 | -1.623M |
| July 28, 2026 | -1.622M |
| July 27, 2026 | -1.604M |
| July 24, 2026 | -1.559M |
| July 23, 2026 | -1.585M |
| July 22, 2026 | -1.473M |
| Date | Value |
|---|---|
| July 21, 2026 | -1.428M |
| July 20, 2026 | -1.423M |
| July 17, 2026 | -1.384M |
| July 16, 2026 | -1.347M |
| July 15, 2026 | -1.338M |
| July 14, 2026 | -1.311M |
| July 13, 2026 | -1.292M |
| July 10, 2026 | -1.220M |
| July 09, 2026 | -1.264M |
| July 08, 2026 | -1.196M |
| July 07, 2026 | -1.282M |
| July 06, 2026 | -1.247M |
| July 02, 2026 | -1.225M |
| July 01, 2026 | -1.130M |
| June 30, 2026 | -1.244M |
| June 29, 2026 | -3.469M |
| June 26, 2026 | -3.482M |
| June 25, 2026 | -3.546M |
| June 24, 2026 | -3.485M |
| June 23, 2026 | -3.478M |
| June 22, 2026 | -3.522M |
| June 18, 2026 | -3.647M |
| June 17, 2026 | -3.382M |
| June 16, 2026 | -3.379M |
| June 15, 2026 | -3.321M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.379B |
| Alnylam Pharmaceuticals, Inc. | 31.79B |
| Anika Therapeutics, Inc. | 273.23M |
| Savara, Inc. | 1.008B |
| Vericel Corp. | 2.144B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.529M |
| Total Expenses (Quarterly) | 2.529M |
| EPS Diluted (Quarterly) | -0.571 |
| Earnings Yield | -663.6% |
| Normalized Earnings Yield | -663.60 |